BRAF V600E

The Bethesda system provides high diagnostic accuracy for definitive cytological categories in pediatric thyroid nodules. Even indeterminate categories carry elevated malignancy risk, supporting careful surgical consideration and the value of BRAF V600E testing for preoperative risk stratification.

Exploratory analysis in a limited TERT cohort (8 mutated vs 103 wild-type) identified prospective radiomics patterns associated with TERT promoter mutations, suggesting potential surrogate imaging biomarkers that warrant further investigation. Micro-CT radiomics shows promise as a complementary tool for diagnostic classification in thyroid cancer and offers a platform for quantitative 3D tissue characterization pending broader validation.

For early-stage POLE-mutated CRC with favorable prognosis, off-label adjuvant immunotherapy may bring unnecessary toxicity risks. It is necessary to conduct rigorous patient selection, comprehensive risk-benefit evaluation, and close monitoring of organ function during treatment, so as to provide reference for the standardized clinical application of ICIs in this population.

ML models that incorporate spectral CT 3D parameters and clinical features offer a promising approach for preoperative prediction of mETE in PTMC. Following external validation in multicenter cohorts, these models may serve as adjunctive tools to inform clinical decision-making and risk stratification.

A combined model integrating US-FNAC and serum BRAF V600E testing improved diagnostic performance, with a sensitivity of 81.25%, specificity of 85.19%, and AUC of 0.873, significantly outperforming either method alone. These findings suggest that serum BRAF V600E detection is a useful complementary, minimally invasive approach for diagnosing PTC, particularly micro-PTC, and may improve early detection and risk stratification when combined with US-FNAC.

Systemic chemotherapy with vinblastine and prednisone led to marked improvement in nail, skin, pulmonary, and osseous lesions. These cases illustrate that nail changes may be the earliest manifestation of LCH and should prompt thorough systemic evaluation. Early recognition of nail involvement can facilitate timely diagnosis and risk-adapted treatment, potentially improving outcomes in affected patients.

P1/2, N=94, Not yet recruiting, Gilead Sciences Inc.

P2, N=7, Terminated, Northwestern University | Trial completion date: Jul 2030 --> Apr 2026 | Active, not recruiting --> Terminated | Trial primary completion date: May 2026 --> Oct 2025; The study was closed due to accrual.

Depending on the Bethesda category, the positive predictive value for malignancy of the seven-gene panel ranged between 18.18% (Bethesda III) and 91.07% (Bethesda V), while the negative predictive value ranged between 93.92% (Bethesda III) and 24.14% (Bethesda V). In conclusion, molecular testing with the seven-gene panel can improve ROM estimation in cytopathologically indeterminate thyroid nodules, but its clinical utility depends on the detected gene alteration.

The LiBRA study supports liquid biopsy as a prognostic and monitoring tool in BRAF V600E-mutated NSCLC undergoing targeted therapy.

Does circulating tumor DNA hold promise for guiding personalized immunotherapy decisions? This review aims to address these questions, while acknowledging that many remain unanswered and are the focus of numerous ongoing studies.

KRAS mutations were more frequent in dMMR tumors than in MMR-proficient tumors (63.8% vs 40.8%).ConclusionGenetic mutations in the RAS/RAF pathway and dMMR status are associated with distinct clinicopathological features in patients with early-onset CRC. dMMR is a potentially favorable prognostic marker.